



**New business models for the healthcare industry**

**Tuesday 26<sup>th</sup> November 2014 – 19h30**

**Goldman Sachs office,**

River Court  
Room 7 G-H  
120 Fleet Street  
London EC4A 2BE

At a time when the industry and its stakeholders have acknowledged that they need to adapt to a new environment, where blockbusters are no longer the driving force in the industry, new disruptive products arise, such as in Hepatitis C for example, and they promise to bring such value to the patients that their cost seem unaffordable.

What are the implications of this new trend? How do policy makers, payers and the financial community intend to navigate the discrepancies between cost effectiveness, affordability and reward for the companies who manage to develop such high value products?

We propose a roundtable discussion involving select stakeholders to explore the impact of highly innovative products in the ecosystem.

*Panel members: TBC*

**Glen Anley**

Analyst at Economist Intelligence Unit Healthcare - Bringing significant provider experience in the gulf

**Andrew Bell**

Founder and Director of Strategy in Life Sciences

**Dr Francois Bernard**

European head market access at Mundipharma

**Claire Briffaut**

Financial Analyst at Guy's and St Thomas NHS foundation trust

**Dr Christophe Griolet**

Associate Director Commercial Planning & Operations at Gilead Sciences